EPR effect based nanocarriers targeting for treatment of cancer

Kavita Rai Gajbhiye, J M Gajbhiye

DOI: http://dx.doi.org/10.5138/09750215.1974

Abstract


The enhanced permeability and retention (EPR) effect is a unique phenomenon of solid tumors related to their anatomical and pathophysiological differences from normal tissues. In solid tumors, angiogenesis leads to high vascular density. Large gaps exist between endothelial cells in tumor blood vessels, which lead to selective extravasations and retention of macromolecular drugs. This EPR effect served as a basis for development of macromolecular anticancer therapy. There are various factors, which lead to a significantly increased EPR effect and enhanced antitumor drug effects as well. This review discusses the unique anatomy of tumor vessels, molecular mechanisms of factors related to the EPR effect and the role of the EPR effect in the intratumoral delivery of protein and peptide drugs, macromolecular drugs and drug-loaded long-circulating nanocarriers.


Keywords


Enhanced permeability retention effect; Passive targeting; Tumor targeting; Nanocarrier

Full Text:

PDF

References


[1]. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-6392.

[2]. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Cancer Res. 1998; 89: 307–314.

[3]. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ. Endothelial function and dysfunction. J Hypertens. 2005; 23: 7–17.

[4]. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Intern Immunopharmacol. 2003; 3: 319-328.

[5]. Torchilin VP. Targeted Pharmaceutical Nanocarriers for Cancer Therapy and Imaging. Am Ass Pharma Sci. J 2007; 2: 123-134.

[6]. Maeda H, Sawa T, Konno T. Mechanism of tumor targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001; 74: 47–61.

[7]. Greiesh K, Iyer AK, Fang J, Kawasuji M, Maeda H. Enhanced permeability and retention (EPR) effect and tumor–selective delivery of anticancer drugs, Editor, Delivery of Protein and Peptide Drugs in Cancer, Imperial College Press, London 2006; 37–52.

[8]. Fox MF, Szoka FC, Frechet MJ. Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture. Acc Chem Res. 2009; 8: 1141–1151.

[9]. Tanaka T,Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm. 2004; 1: 39-61.

[10]. Friend DR, Pangburn S. Site-specific drug delivery. Med. Res. Rev. 1987; 7: 53–106.

[11]. Hockel S, Schlenger K, Vaupel P, Hockel M. Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer. Int J Oncol. 2001; 4: 827-32.

[12]. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med. 1995; 1: 27–31.

[13]. Fang J, Sawa T, Maeda H. Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol. 2003; 519: 29–49.

[14]. Seki T, Fang J, Maeda H. Tumor targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor. Pharm Perspectives Cancer Ther. 2009; 93–120.

[15]. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs and nanomedicines for efficient tumor targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009; 71: 409–419.

[16]. Jang SH, Wientjes MG, Lu D, Au JLS. Drug delivery and transport to solid tumor. Pharm Res. 2003; 9: 1337-1350.

[17]. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and Carriers. Amer Ass Pharma Sci J. 2010; 12: 492–503.

[18]. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4: 806-813.

[19]. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumor targeting. Clin Pharmacokinet. 2003; 42: 1089–1105.

[20]. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 1992; 52: 5110–5114.

[21]. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Bio. 2010; 2: 759-768.

[22]. Maeda H, Muzykantov V, Torchilin VP. Enhanced permeability and retention (EPR) effect : basis for drug targeting to tumors, Editors, Biomedical Aspects of Drug Targeting, Kluwer Academic Publishers 2003; 211–228.

[23]. Duncan R. Polymer-drug conjugates. In: Budman D, Calvert H, Rowinsky E. Handbook of Anticancer Drug Development. Baltimore, MD: Lippincott Williams & Wilkins; 2003; 239-260.

[24]. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006; 6: 688-701.

[25]. Satchi FR, Duncan R, Barnes CM. Polymer therapeutics for cancer: current status and future challenges. Adv Polym Sci. 2006; 1-65.

[26]. Sahoo SK. Pegylated zinc protoporphyrin: a water-soluble hemeoxygenase inhibitor with tumor-targeting capacity. Bioconjug Chem. 2002; 13: 1031–1038.

[27]. Greish K. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release. 2004; 97: 219–230.

[28]. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006; 24: 39–47.

[29]. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268: 235–237.

[30]. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating. Adv Drug Deliv Rev. 1995; 16: 141–155.

[31]. Hobbs SK, Yuan MF, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. PNAS. 1998; 95: 4607–4612.

[32]. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55: 3752–3756.

[33]. Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008; 121: 637–645.

[34]. Santos ND, Allen C, Doppen AM, Anantha M, Cox KAK, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta Biomembranes. 2007; 1768: 1367–1377.

[35]. Vasey PA, Kaye SB, Morrison R. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Can Res. 1999; 5: 83–94.

[36]. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opinion on Pharmacother. 2009; 10: 333–343.

[37]. Kalra AV, Campbell RB. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharmaceu Res. 2006; 23: 2809–2817.

[38]. Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, Teifel M, Alken P, Michel MS. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep. 2009; 22: 321–326.

[39]. Ko YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mole Pharm. 2009; 6: 971–977.

[40]. Wu J, Lee A, Lu YH, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm. 2007; 337: 329–335.

[41]. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991; 1068: 133–141.

[42]. Nag M, Gajbhiye V, Kesharwani P, Jain NK. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells. Colloids Surf B: Biointerfaces. 2016, 148: 363-370.

[43]. Jong HK, Yoo SK, Kyeongsoon P, Seulki L, Hae YN. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release. 2008; 127: 41–49.

[44]. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53: 283–318.

[45]. Mitraa S, Gaura U, Ghosha PC, Maitrab AN. Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release. 2001; 74: 317–323.

[46]. Etame AB, Smith CA, Chan WC, Rutka JT. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine. 2011; 7: 992-1000.

[47]. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Del Rev. 2011; 63: 170–183.

[48]. Conroy S, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Del Rev. 2008; 60: 1252–1265.

[49]. Hai W , Ying Z, Yan W, Yu H, Kaihui N, Guangjun N, Hao C. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011; 32: 8281-8290.

[50]. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 5: 271–284.

[51]. Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech. 2009; 10: 1186-1192.

[52]. Tiwari AK, Gajbhiye V, Sharma R, Jain NK. Carrier mediated protein and peptide stabilization. Drug delivery. 2010; 17: 605-616.

[53]. Mauer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001; 6: 923–947.

[54]. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42: 419–436.

[55]. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005; 2: 369–381.

[56]. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev. 2001; 53: 285–305.

[57]. Allen C, Santos ND, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep. 2002; 22: 225–250.

[58]. Allen TM, Hansen C, Martin F, Redemann C, Young AY. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991; 1066: 29–36.

[59]. Blume G, Cevc C. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta. 1990; 1029: 91–97.

[60]. Zalipsky S, Qazen M, Walker JA, Mullah N, Quinn YP, Huang SK. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem. 1999; 10: 703–707.

[61]. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP. SMART drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006; 17: 943–949.

[62]. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther. 1997; 280: 1406–1414.

[63]. Wang J, Goh B, Lu W. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull. 2005; 28: 822–828.

[64]. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev. 1995; 16: 285–294.

[65]. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001; 19: 424–436.

[66]. Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer. 2001; 85: 1850–1852.

[67]. Rouf MA, Vural I, Renoir JM, Hincal AA. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J Liposome Res. 2009; 19: 322-331.

[68]. Morawski AM, Lanza GA, Wickline SA. Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol. 2005; 16: 89-92.

[69]. Ogawara KI, Keita U, Minato K, Tanakab KI, Higaki K, Kimura T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors. Int J Pharm. 2008; 359: 234–240.

[70]. Man YW, Gigi NC. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine. 2011; 7: 834-840.

[71]. Gajbhiye V, Kumar PV, Sharma A, Jain NK. Novel PEGylated PPI dendritic nanostructures for sustained delivery of anti-inflammatory agent. Curr Nanoscience. 2008; 4: 267-277.

[72]. Patel SK, Gajbhiye V, Jain NK. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates. J Drug Target. 2012; 20: 841-84.

[73]. Patel HK, Gajbhiye V, Kesharwani P, Jain NK. Ligand anchored poly (propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. J Colloid Interface Sci. 2016; 482: 142-150.

[74]. Wijagkanalan W, Kawakami S, Hashida M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm Res. 2011; 7 1500-1519.

[75]. Gajbhiye V, Kumar PV, Tekade RK, Jain NK. Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Design. 2007; 13: 415-429.

[76]. Cameron CL, Elizabeth RG, Megan EF, Guillaudeu SJ, Jean MJ. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. PNAS. 2006; 3: 422-449.

[77]. Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm. 2010; 383: 293–296.

[78]. Okuda T, Kawakami S, Akimoto N, Niidome T, Yamashita F, Hashida M. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Release. 2006; 3: 330-336.

[79]. Alcala MA, Shade CM, Uh H, Kwan SY, Bischof M, Thompson ZP. Preferential accumulation within tumors and in vivo imaging by functionalized luminescent dendrimer lanthanide complexes. Biomaterials. 2011; 32: 9343-9352.

[80]. Kayat J, Mehra NK, Gajbhiye V, Jain NK. Drug targeting to arthritic region via folic acid appended surface-engineered multi-walled carbon nanotubes. J Drug Target. 2016; 24: 318-327.

[81]. Shun J, Liu C, Zhang B, Yang F, Xu J, Long J. Carbon nanotubes in cancer diagnosis and therapy. Reviews Cancer. 2010; 1: 29-35.

[82]. Zhuang L, Chen K, Davis C, Sherlock S. Drug Delivery with Carbon Nanotubes for In vivo Cancer Treatment. Cancer Res. 2008; 68: 6652-6660.

[83]. Cheng J, Meziani MJ, Sun YP, Cheng SH. Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming m ultidrug resistance. Toxicol Appl Pharmacol. 2011; 250: 184-193.

[84]. Cheung W, Pontoriero F, Taratula O, Chen AM, He H. DNA and carbo n nanotubes as medicine. Adva Drug Del Rev. 2010; 62: 633-649.

[85]. Zhang Y, Bai Y, Yan B. Functionalized carbonnanotubes for potential medicinal applications. Drug Dis Today. 2010; 15: 428-435.

[86]. Patrics J. Carbon Nanotube-Based Drug Delivery Systems. Brookhaven Science Associates. LLC. 2011; 321-357.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 Kavita Rai Gajbhiye

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Advanced Research Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India

Copyright@arjournals.org (Design) 2009-2016

 

Follow @arjournals on Twitter